TARGET PRODUCT PROFILE FOR THERAPY OF UNCOMPLICATED ENTERIC FEVER
Target product profile for therapy of uncomplicated enteric fever.

ISBN 978-92-4-000384-2 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.


Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by Phoenix Design Aid
Target product profile for therapy of uncomplicated enteric fever

Introduction

Disease burden
Enteric fever, mostly referred to as typhoid fever, is a systemic infection caused by Salmonella Typhi (S. enterica subsp. enterica, serovar Typhi) or Salmonella Paratyphi (S. enterica subsp. enterica, serovar Paratyphi). Enteric fever is a poverty-related disease, common in countries with inadequate water and sanitation infrastructure. Infection with S. Typhi or the less common S. Paratyphi is estimated to have caused 14.3 million cases and 135,900 deaths worldwide in 2017 with higher case fatality estimates among children and older adults, and among those living in lower-income countries. The highest burden of disease occurs in South and South-East Asia and in sub-Saharan Africa, and in children < 5 years old and, in some countries, young adults. Food-related outbreaks occur in high-income countries (HICs) as well as in travellers who return from countries where enteric fever is endemic.

Antibiotic resistance
Multidrug-resistant (MDR) S. Typhi strains, resistant to three or more antibiotic categories, are common. Extensively drug resistant (XDR) S. Typhi strains, resistant to all but one or two antibiotic categories, have emerged in Pakistan. The XDR strains are resistant to all major antibiotic categories used for treatment over the last 7 decades and have a large number of resistance determinants. In addition to chromosomal resistance determinants, resistance genes can also be carried on transferable plasmids. The evolution and spread of MDR strains can take different paths in different regions of the world. In some Asian countries, ciprofloxacin resistance in S. Typhi or S. Paratyphi is close to 100%.

Available treatment options
Traditional therapies, including ampicillin, chloramphenicol, co-trimoxazole and fluoroquinolones, are not effective in many regions. In particular, fluoroquinolones are not effective against S. Typhi or S. Paratyphi in South Asia. Antibiotic treatment options for MDR strains are usually cefixime (an oral cephalosporin), azithromycin (an oral azalide) and ceftriaxone (an intravenous/intramuscular cephalosporin). The only active treatments for XDR strains documented in Pakistan are azithromycin and carbapenems. Intravenous treatment with carbapenems is not available or affordable for most patients in countries endemic for enteric fever.

Therapies in development
Current research and investment focuses not on new antibiotic treatments, but on vaccine development and, to a lesser degree, diagnostics. An improved conjugate vaccine (Typbar TCV) was
pre-qualified by the World Health Organization (WHO) in December 2017. However, resistance to first- and second-line antibiotics is a public health concern and requires the development of new antibiotics. There are potentially suitable antibiotics in preclinical development, but not in clinical development. The target product profile (TPP) for a new antibiotic against *S*. Typhi and *S*. Paratyphi should address the need for a new class of drug with no cross-resistance to existing drugs used for treatment of enteric fever.

**Purpose of the TPP**

This TPP should guide the clinical development of a new antibiotic for the treatment of acute infection and prevention of carrier state in endemic or outbreak settings with bacteriologically confirmed MDR and XDR *S*. Typhi or *S*. Paratyphi. The new treatment should have excellent penetration into intracellular (preferred) and extracellular compartments, and lead to rapid clinical (fever defervescence) and microbiological clearance (blood culture negativity). It should be suitable for use in children with intravenous and oral formulations with a good bioavailability. Hepatic clearance is preferred, as a high liver clearance is required to eliminate convalescent faecal shedding and carrier state.

A new antibiotic against *S*. Typhi and *S*. Paratyphi may also be effective against invasive non-typhoidal *Salmonella* infection and potentially in *Shigella* infection. The predicted rise in environmental disasters, such as flooding, could significantly increase the risks of enteric fever and the need for new antibiotics in the future. Antibiotic research efforts should go hand in hand with the development of corresponding rapid diagnostics that are inexpensive and identify the pathogen as well as the susceptibility profile.

**Access and affordability**

- Access to new essential antibacterial treatments is an essential part of universal health coverage. Developers should commit to an access and stewardship strategy that promotes availability at fair prices. A fair price is one that is affordable for health systems and patients, but at the same time provides sufficient market incentive for industry to invest in innovation and the production of quality essential health products. To ensure access to patients in many countries, developers are invited to collaborate with WHO, the Global Antibiotic Research and Development Partnership and the Medicines Patent Pool where appropriate.

- Governments need to commit to ensure availability and affordability of essential new antibiotic treatments. In particular for reserve antibiotics, governments should explore models where procurement and reimbursement are linked to availability instead of volume to foster appropriate use.

- Stewardship and appropriate use are essential to preserve the effectiveness of any new antibacterial treatment. Developers should not register the product for use in animals or plants or develop a treatment of the same class for use in animals or plants. The above-mentioned access and stewardship plan should be based on ethical promotion and distribution. Manufacturing should be in line with best industry practices in the management of emissions to the environment to minimize the risks of spreading antimicrobial resistance.
### TPP for therapy of uncomplicated enteric fever

<table>
<thead>
<tr>
<th></th>
<th>Minimal TPP</th>
<th>Preferred TPP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indication for use</strong></td>
<td>Suspected or confirmed uncomplicated enteric fever.</td>
<td>Suspected or confirmed uncomplicated enteric fever (diagnosed by blood culture). Treatment of acute infection, including prevention of carrier state.</td>
</tr>
<tr>
<td><strong>Target population</strong></td>
<td>Adults, children</td>
<td>Adults, children</td>
</tr>
<tr>
<td><strong>Access and affordability</strong></td>
<td>See Introduction and paragraph on Access and affordability.</td>
<td>See Introduction and paragraph on Access and affordability.</td>
</tr>
<tr>
<td><strong>Safety/tolerability</strong></td>
<td>Clinical safety comparable to current therapies.</td>
<td>Clinical safety comparable to current therapies, good tolerability in children.</td>
</tr>
<tr>
<td><strong>In vitro activity</strong></td>
<td>In vitro activity against S. Typhi and S. Paratyphi, low cross-resistance to known antibiotic classes, intracellular activity. Low propensity for mutational resistance development.</td>
<td>In vitro activity against S. Typhi and S. Paratyphi, no cross-resistance to known antibiotic classes, intracellular activity. Low propensity for mutational resistance development.</td>
</tr>
<tr>
<td><strong>Clinical efficacy</strong></td>
<td>Non-inferior clinical activity in acute enteric fever to current therapies in susceptible strains, low relapse rate (&lt; 5%), clinical activity in infections due to pathogens resistant to current therapies.</td>
<td>Non-inferior clinical activity in acute enteric fever to current therapies in susceptible strains, low relapse rate (&lt; 5%), prevent convalescent faecal shedding, clinical activity in infections due to pathogens resistant to current therapies.</td>
</tr>
<tr>
<td><strong>Formulation/presentation</strong></td>
<td>Tablets/capsules, injectables</td>
<td>Tablets/capsules, paediatric suspension with acceptable taste, injectables</td>
</tr>
<tr>
<td><strong>Dose regimen</strong></td>
<td>1-3x daily, treatment duration up to 14 days</td>
<td>1-2x daily, treatment duration up to 7 days</td>
</tr>
<tr>
<td><strong>Route of administration</strong></td>
<td>Oral, or oral + intravenous (iv)</td>
<td>Oral, or oral + iv</td>
</tr>
<tr>
<td><strong>Product stability and storage</strong></td>
<td>Heat stable, 3-year shelf life in hot tropic/humid climate (simulated with 30°C and 65% relative humidity).</td>
<td>Heat stable, 3-year shelf life in hot tropic/humid climate (simulated with 30°C and 65% relative humidity). Stability of formulated suspension for multiple days without refrigeration.</td>
</tr>
<tr>
<td><strong>Pharmacokinetics</strong></td>
<td>Pharmacokinetic data available to support use in acute infections, intracellular penetration and biliary excretion.</td>
<td>Pharmacokinetic data available to support use in acute infections, including children, older patients (&gt; 65 years), patients with some renal or hepatic insufficiency, intracellular penetration and biliary excretion.</td>
</tr>
<tr>
<td><strong>Drug interactions</strong></td>
<td>Comparable to current therapies, no drug-drug interactions (DDIs) with commonly prescribed drugs in the patient population.</td>
<td>Comparable to current therapies, no DDIs with commonly prescribed drugs in the patient population.</td>
</tr>
</tbody>
</table>
**Important documents**


**References**


